Purple Biotech

Purple Biotech P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Purple Biotech (PPBT.TA) as of Oct 28, 2026 is -0.42. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -0.30 — a change of 38.69% (lower).

P/CF

-0.42

YoY

38.69%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Purple Biotech is 2024 -0.42 . P/CF (Price-to-Cash-Flow Ratio) of Purple Biotech was 2023 -0.30 . It decreases by 38.69% lower compared to the previous year.

The Purple Biotech P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2017
-0.69 USD
Jan 1, 2018
-0.71 USD
Jan 1, 2019
-1.07 USD
Jan 1, 2020
-0.43 USD
Jan 1, 2021
-0.39 USD
Jan 1, 2022
-0.36 USD
Jan 1, 2023
-0.30 USD
Jan 1, 2024
-0.42 USD
The Purple Biotech P/CF history
YEARP/CFYoY
-0.42+38.69%
-0.30-16.01%
-0.36-8.87%
-0.39-9.53%
-0.43-59.55%
-1.07+51.94%
-0.71+1.73%
-0.69-27.41%
-0.96-47.17%
-1.81+36.82%
-1.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Purple Biotech Stock analysis

What does Purple Biotech do? Purple Biotech Ltd. develops pharmaceutical products including NT-219, a small molecule bi-specific inhibitor targeting two key cancer resistance pathways, and CM-24, a monoclonal antibody blocker. The company also owns Consensi, a fixed-dose combination of celecoxib and amlodipine besylate designed for treating osteoarthritis pain and hypertension simultaneously. These products are developed for clinical use in oncology and chronic condition management, with NT-219 and CM-24 focused on cancer treatment and Consensi addressing dual therapeutic needs in musculoskeletal and cardiovascular health. The company generates revenue through the development and potential future commercialization of its drug portfolio. NT-219 and CM-24 are in development for oncology applications, while Consensi is positioned as a fixed-dose combination for osteoarthritis and hypertension. The target market includes healthcare providers and patients requiring treatments for cancer, osteoarthritis, and hypertension, with Consensi offering a dual therapy solution that may appeal to patients managing multiple chronic conditions. Purple Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Purple Biotech stock

P/CF (Price-to-Cash-Flow Ratio) of Purple Biotech is -0.42 in 2024.

P/CF (Price-to-Cash-Flow Ratio) of Purple Biotech changed from -0.30 to -0.42, representing a 38.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Purple Biotech since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Purple Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Purple Biotech

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Purple Biotech